Patents by Inventor Agustin Casimiro-Garcia

Agustin Casimiro-Garcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
    Patent number: 9617258
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof, having the structure: or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer or diastereomer thereof, as set forth in the Description. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla, John I. Trujillo
  • NOVEL PYRIDINE PYRAZINONES AS BET-FAMILY BROMODOMAIN INHIBITORS
    Publication number: 20160368919
    Abstract: Disclosed are novel pyridine pyrazinones or pharmaceutically acceptable salts thereof. Pharmaceutical compositions and the use of the compounds to treat diseases or disorders that are BET family bromodomain-dependent are also disclosed. Methods for preparing and using these compounds are further described.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 22, 2016
    Applicant: Pfizer Inc.
    Inventors: Agustin Casimiro-Garcia, Bruce Allen Lefker, Nikolaos Papaioannou, Arjun Venkat Narayanan, Jotham Wadsworth Coe
  • PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES
    Publication number: 20150158864
    Abstract: The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
    Type: Application
    Filed: December 3, 2014
    Publication date: June 11, 2015
    Inventors: Atli Thorarensen, Matthew Frank Brown, Agustin Casimiro-Garcia, Ye Che, Jotham Wadsworth Coe, Mark Edward Flanagan, Adam Matthew Gilbert, Matthew Merrill Hayward, Jonathan David Langille, Justin Ian Montgomery, Jean-Baptiste Telliez, Rayomand Jal Unwalla
  • 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES
    Publication number: 20120022058
    Abstract: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.
    Type: Application
    Filed: March 26, 2010
    Publication date: January 26, 2012
    Inventors: Graciela Barbieri Arhancet, Agustin Casimiro-Garcia, Xiangyang Chen, David Hepworth, Marvin Jay Meyers, David Walter Piotrowski, Raj Kumar Raheja
  • MORPHOLINE COMPOUNDS
    Publication number: 20110281854
    Abstract: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.
    Type: Application
    Filed: May 10, 2011
    Publication date: November 17, 2011
    Inventors: Agustin Casimiro-Garcia, Kentaro Futatsugi, David W. Piotrowski
  • COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES
    Publication number: 20100029710
    Abstract: Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure, and hypertension.
    Type: Application
    Filed: December 3, 2007
    Publication date: February 4, 2010
    Applicant: Pfizer Products Inc.
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Chitase Lee, Hud Lawrence Risley, Robert Philip Schaum
  • INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
    Publication number: 20090221546
    Abstract: Compounds useful as intermediates for synthesis of compounds of Formula (1): wherein A, B, C, G, and W1 have any of the values defined in the specification.
    Type: Application
    Filed: June 16, 2008
    Publication date: September 3, 2009
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Danette Andrea Dudley, Jeremy John Edmunds, Kevin James Filipski, Jeffrey Thomas Kohrt, Chad Alan Van Huis
  • Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade
    Publication number: 20080287674
    Abstract: Compounds useful as intermediates for synthesis of compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification.
    Type: Application
    Filed: June 26, 2008
    Publication date: November 20, 2008
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Danette Andrea Dudley, Jeremy John Edmunds, Kevin James Filipski, Jeffrey Thomas Kohrt, Chad Alan Van Huis
  • Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
    Patent number: 7407974
    Abstract: The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
    Type: Grant
    Filed: April 18, 2005
    Date of Patent: August 5, 2008
    Assignee: Pfizer Inc.
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Danette Andrea Dudley, Jeremy John Edmunds, Kevin James Filipski, Jeffrey Thomas Kohrt, Chad Alan Van Huis
  • INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
    Publication number: 20060264626
    Abstract: Compounds useful as intermediates for synthesis of compounds of Formula (1): wherein A, B, C, G, and W1 have any of the values defined in the specification.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 23, 2006
    Inventors: Agustin Casimiro-Garcia, Jeremy Edmunds, Kevin Filipski, Jeffrey Kohrt
  • Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
    Patent number: 7030141
    Abstract: The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: April 18, 2006
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Danette Andrea Dudley, Jeremy John Edmunds, Kevin James Filipski, Jeffrey Thomas Kohrt, Chad Alan Van Huis
  • Inhibitors of fractor Xa and other serine proteases involved in the coagulation cascade
    Publication number: 20050250815
    Abstract: The present invention provides compounds of Formula (I): wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.
    Type: Application
    Filed: April 18, 2005
    Publication date: November 10, 2005
    Inventors: Christopher Bigge, Agustin Casimiro-Garcia, Danette Dudley, Jeremy Edmunds, Kevin Filipski, Jeffrey Kohrt, Chad Van Huis
  • Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
    Publication number: 20030220315
    Abstract: Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.
    Type: Application
    Filed: May 27, 2003
    Publication date: November 27, 2003
    Inventors: Mark S. Cushman, Agustin Casimiro-Garcia, William G. Rice
  • Antidiabetic agents
    Publication number: 20030171377
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: August 22, 2002
    Publication date: September 11, 2003
    Inventors: Christopher Franklin Bigge, Alexander James Bridges, Agustin Casimiro-Garcia, Stephen Alan Fakhoury, Helen Tsenwhei Lee, Jessica Reed, Robert Schaum, Kevin Matthew Schlosser, Karen Sexton, Hairong Zhou
  • Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
    Publication number: 20030162787
    Abstract: The present invention provides compounds of Formula (I): 1
    Type: Application
    Filed: October 23, 2002
    Publication date: August 28, 2003
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Danette Andrea Dudley, Jeremy John Edmunds, Kevin James Filipski, Jeffrey Thomas Kohrt, Chad Alan Van Huis
  • Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
    Patent number: 6569897
    Abstract: Alkenyldiarylmethane (ADAM) compounds have been found effective as anti-HIV agents. Novel ADAM compounds, their pharmaceutical formulations and a method of using same to treat viral infections are described.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: May 27, 2003
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health & Human Services
    Inventors: Mark S. Cushman, Agustin Casimiro-Garcia, William G. Rice